{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"12"},{"groupId":"OG001","value":"29"}]}],"title":"Phlebotomy frequency: >0 - <=2"},{"categories":[{"measurements":[{"groupId":"OG000","value":"7"},{"groupId":"OG001","value":"17"}]}],"title":"Phlebotomy frequency: >2 - <=4"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4"},{"groupId":"OG001","value":"2"}]}],"title":"Phlebotomy frequency: >4 - <=6"},{"categories":[{"measurements":[{"groupId":"OG000","value":"0"},{"groupId":"OG001","value":"1"}]}],"title":"Phlebotomy frequency: >6 - <=8"}],"denoms":[{"counts":[{"groupId":"OG000","value":"74"},{"groupId":"OG001","value":"75"}],"units":"Participants"}],"description":"Phlebotomy eligibility was defined by Confirmed Hct \\> 45% that is at least 3 percentage points higher than the Hct obtained at Baseline Or Confirmed Hct \\> 48%. The confirmation occurred 2 to 14 days subsequent to the initial observation.","groups":[{"description":"Ruxolitinib at a starting dose of 10 mg twice a day (bid). Dose was adjusted based on efficacy and safety parameters up to a maximum dose of 25 mg bid","id":"OG000","title":"Ruxolitinib"},{"description":"Best Available Therapy as selected by the investigator from: Hydroxyurea, Pegylated-Interferon (IFN/PEG-IFN), pipobroman, anagrelide, IMIDs, or observation. Participants randomized to BAT who did not respond by Week 28 were eligible to crossover and start treatment with ruxolitinib","id":"OG001","title":"Best Available Therapy (BAT)"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"Full Analysis Set (FAS) included all participants to whom study treatment was assigned by randomization and had valid measurements for the outcome measure.","reportingStatus":"POSTED","timeFrame":"Baseline to Week 260","title":"Number of Participants With Phlebotomies Over Time","type":"SECONDARY","unitOfMeasure":"Participants"}